Diaceutics (LON:DXRX) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Diaceutics (LON:DXRX) in a research note issued to investors on Tuesday,Digital Look reports. Canaccord Genuity Group currently has a GBX 160 ($2.03) price target on the stock.

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 160 ($2.03) price target on shares of Diaceutics in a research note on Tuesday.

Diaceutics Price Performance

DXRX stock traded down GBX 3.50 ($0.04) during mid-day trading on Tuesday, hitting GBX 120.50 ($1.53). The company had a trading volume of 35,123 shares, compared to its average volume of 108,035. The company has a market capitalization of £101.79 million, a price-to-earnings ratio of -4,016.67 and a beta of 0.58. The company has a 50-day moving average price of GBX 122.28 and a 200 day moving average price of GBX 126.30. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. Diaceutics has a 12-month low of GBX 84.50 ($1.07) and a 12-month high of GBX 136 ($1.73).

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.